Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Prospective, Comparative Study of the Effectiveness of Prophylactic Entecavir Treatment for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation

NCT04942886 is registered in ClinicalTrials.gov with Seoul St. Mary's Hospital as lead sponsor.

NCT NCT04942886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04942886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Prospective, Comparative Study of the Effectiveness of Prophylactic Entecavir Treatment for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
Lead sponsor
Seoul St. Mary's Hospital
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
August 21, 2021
Completion date
December 31, 2028
Enrollment
226 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiviral drug, hbv, hematopoietic stem cell transplantation, hepatitis b reactivation